Global Rare Hemophilia Factors Market, By Type (Factor I, Factor II, Factor V, Factor VII, Factor X, Factor XI, Factor XIII), Application (Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Rare haemophilia factors sector is expected to increase at a healthy rate, in the coming years. Hematologists are paying more attention to various discovery processes as multiple blood-related disorders such as myeloma, anaemia, sickle cell anaemia, and leukaemia have increased. Haematologists prefer improved treatment processes over precise diagnosis procedures.
Data Bridge Market Research analyses that the rare hemophilia factors market which was USD 78.83 billion in 2021, would rocket up to USD 126.59 billion by 2029, and is expected to undergo a CAGR of 6.10% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Factor I, Factor II, Factor V, Factor VII, Factor X, Factor XI, Factor XIII), Application (Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Baxter (U.S), Bayer AG (Germany), Bio Products Laboratory Ltd. (U.K), Biogen (U.S), CSL (U.S), Novo Nordisk A/S (Denmark), Pfizer, Inc. (U.S), Takeda Pharmaceutical Co. Ltd. (Japan), Alexion Pharmaceuticals, Inc (U.S), Shire plc (U.S), ICON plc (U.S), Amgen Inc (U.S), BioMarin (U.S)
|
|
Market Opportunities
|
|
Market Definition
Hemophilia is an uncommon disorder in which the blood does not clot properly due to a deficiency in blood-clotting proteins (clotting factors). If you have haemophilia, you may bleed for longer periods of time following an accident than if your blood clots normally. Small cuts are usually not a big deal.
Rare Hemophilia Factors Market Dynamics
Drivers
- New technological advancements
Several concentrations have recently acquired marketing permission from regulatory organisations. Coagadex, for example, was approved by the FDA in October 2015 for the treatment of hereditary factor X deficiency. In 2011, the FDA approved CSL Behring's product Corifact for the treatment of congenital factor XIII (FXIII) deficiency. The introduction of new items is anticipated to boost the market. Patients will be more aware of innovative concentrations if they are more widely available. They will also have more therapy options.
- Rising adoption of prophylactic treatments
Patients' increasing use of preventative therapies is also contributing to the market's rise. Prophylaxis has a number of advantages, including a lower risk of joint pain and damage. Prophylactic medication is indicated for patients with severe uncommon haemophilia disorders to prevent bleeding episodes and improve quality of life. For example, both adult and paediatric patients with congenital factor XIII A-subunit deficiency should receive long-term preventive treatment with NovoThirteen (rFXIII-A). Continuous treatment improves the efficacy and performance of prophylaxis, resulting in a higher adoption rate. As a result, market growth is expected to accelerate throughout the forecast period.
- Research and development activities
Attempts by the International Rare Disorders Research Consortium (IRDiRC) in Europe to create 200 novel medicines for such diseases by 2020, as well as funding for studies and R&D activities, are likely to boost the market for haemophilia factors. Furthermore, actions conducted by patient advocacy groups, academic institutions, other nonprofit organisations, and pharmaceutical businesses drives regional markets.
Opportunities
Patients and practitioners are becoming more aware of the rare haemophilia coagulation diseases due to government initiatives and mandates, which has increased diagnostic and treatment rates for this condition. As a result, the market's growth is expected to accelerate throughout the forecast period. For example, the United States Congress passed the Orphan Drug Act (ODA) in 1983. Between 1983 and 2015, around 3,647 medicines were designated as orphan medications, with the FDA approving 554 of them. These orphan drug approvals have resulted in better treatment options for people suffering from uncommon diseases such rare haemophilia disorders.
Restraints/Challenges
Increased risk of joint damage, increased risk of spontaneous bleeds, causes problems with blood clotting, these are some factors which will hamper the growth of the rare hemophilia factors market in the forecast period.
This rare hemophilia factors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the rare hemophilia factors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Rare Hemophilia Factors Market Scope
The rare hemophilia factors market is segmented on the basis of type, treatment. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Factor I
- Factor II
- Factor V
- Factor VII
- Factor X
- Factor XI
- Factor XIII
Treatment
- Factor Concentrates
- Fresh Frozen Plasma
- Cryoprecipitate
- Others
Rare Hemophilia Factors Market Regional Analysis/Insights
The rare hemophilia factors market is analysed and market size insights and trends are provided by country, type, treatment as referenced above.
The countries covered in the rare hemophilia factors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, sEgypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to government initiatives to upsurge the rate of diagnosis and reduce treatment costs and research activities to improve management of rare hemophilia conditions.
Asia-Pacific is expected to witness the highest growth over the forecast period owing to the growing population and increasing incidence of autosomal recessive disorders.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Rare Hemophilia Factors Market Share Analysis
The rare hemophilia factors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to rare hemophilia factors market.
Some of the major players operating in the rare hemophilia factors market are:
- Baxter (U.S)
- Bayer AG (Germany)
- Bio Products Laboratory Ltd. (U.K)
- Biogen (U.S)
- CSL (U.S)
- Novo Nordisk A/S (Denmark)
- Pfizer, Inc. (U.S)
- Takeda Pharmaceutical Co. Ltd. (Japan)
- Alexion Pharmaceuticals, Inc (U.S)
- Shire plc (U.S)
- ICON plc (U.S)
- Amgen Inc (U.S)
- BioMarin (U.S)
SKU-